Open company graph database — free web & API
Login

REPROCELL USA Inc.

REPROCELL USAAliasREPROCELL USA, Ltd.AliasREPROCELL USA株式会社Alias
Ticker
—
Listed market
—
Country
United States of America
Employees (non-consolidated)
—
Related companies
8
§01

Basic information

BASIC
Head office
Beltsville, MD, U.S.A.
Chief executive
Chikafumi Yokoyama
Employees (non-consolidated)
Employees (consolidated)
Start date
2003-02-01
End date
§02

Websites

1 DOMAINS
§03

Business

71
LabwareGMP-grade iMSC & MSC productionClinical-grade stem cell and gene editing servicesClinical Stem Cell ServicesStemEdit License-Free Gene EditingGenomic & Bioinformatics ServicesGMP iPSC & iMSC MCB ManufacturingiPSC-Derived Exosome Production ServiceRegenerative Medicine ProductsCustom Research Stem Cell ServicesCustom ReprogrammingExpansion & CharacterizationNucleic Acid ExtractionReal-Time PCRBiomarker Discovery and ValidationNext-Generation SequencingOligonucleotide Synthesis ServiceNeoantigen Detection ServiceCellular ServicesCentral Lab ServicesBiomarker ServicesMolecular ServicesProject ManagementCells and products for stem cell research and 3D cell cultureStem Cell ReagentsRNA ReprogrammingSmall MoleculesGene Editing ProductsStemfactor Growth Factors and CytokinesQkine Growth Factors and CytokinesAntibodies and Staining KitsStem Cell Culture MediaCell SubstratesCryopreservation MediaDissociation SolutionsTransfection ReagentsCellsStem Cell Products3D Cell CultureAlvetex systemsRNA reprogrammingCDMO services for clinical MSC and MSC-derived ATMPsResearch Cell LinesResearch iPSC linesiPSC-derived MSCs (iMSCs)Hypoimmune B2M/CIITA cell linesBioengineered Tissues3D Cell Culture Productscontract research services in human ex vivo living tissuesdrug-efficacy-safety-admediagnostic servicesclinical research servicesculture media for human ES/iPS cellsculture reagentscardiomyocytes derived from human iPS cellsneurons derived from human iPS cellsstem cell-based drug development support technologiespatient recruitmentaccess to human biospecimens and diagnosticsproviding researchers around the world with access to human tissue samples from diseased donors, climolecular biology servicespredictive drug discovery servicesbioengineered tissue model serviceshuman tissue acquisition3D technologiesdrug discoveryiPSC-derived human cardiomyocytes, hepatocytes, and neuronal cells for research applicationsPersonal iPS ServicePCR Testing Service for COVID-19New Testing Service of Identification for Covid-19 VariantsNIPT clinical services
§04

Related companies

8 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
REPROCELL Europe Ltd.
Group
Bioserve Biotechnologies (India) Private Ltd.
Group
Lantern Pharma Inc.
Maryland Stem Cell Research Fund
Prince George's County Economic Development Corporation
ReproCell Co., Ltd.
Steminent Biotherapeutics Inc.
panCELLa/Implant Therapeutics
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

2 EVENTS

Established in 2003 by preeminent Japanese university researchers, REPROCELL quickly became the leading stem cell research company in Japan.Sources

We were the first company to offer iPSC-derived human cardiomyocytes, hepatocytes, and neuronal cells for research applications and were listed on the Japan JASDAQ / Growth stock market in 2013.Sources

§07

News

22 ARTICLES

REPROCELL Launches REPROSKIN™Sources

REPROCELL Europe Ltd has launched REPROSKIN™, a bioengineered full-thickness human skin model. Scientists can purchase it for in-house research or access testing through REPROCELL’s contract research services. The model uses the company’s Alvetex® scaffold technology.

REPROCELL and Polyphron Collaborate on AI-Driven Human Tissue ResearchSources

REPROCELL and Polyphron announced a collaboration to supply REPROCELL's StemRNA™ iPSCs to Polyphron's artificial human biology platform. The companies aim to advance research by combining iPSC technology with AI-driven tissue manufacturing.

REPROCELL Expands iPSC in ChinaSources

REPROCELL Inc. announced a strategic collaboration with WEIPU Biotechnology Co., Ltd. in Suzhou, China, to provide cell therapy developers with access to StemRNA™ Clinical iPSC technologies and iPSC‑derived mesenchymal stem cell seed and master cell banks, supporting high‑quality clinical starting materials and complementary biological testing services.

REPROCELL Submits Japanese Marketing Approval Application for Stemchymal® for SCA3 and SCA6Sources

REPROCELL Inc. submitted an application in Japan for manufacturing and marketing approval of Stemchymal®, a regenerative medicine product intended to slow the progression of ataxia in patients with SCA3 and SCA6. Steminent Biotherapeutics Inc. of Taiwan will manufacture the product, while REPROCELL will oversee sales and distribution in Japan. Stemchymal® has been designated an orphan drug.

REPROCELL Secures MSCRF AwardSources

REPROCELL (TYO: 4978) announced that it has received a competitive Commercialization Award from the Maryland Stem Cell Research Fund (MSCRF). The award will fund the development of clinical‑grade, hypoimmune induced pluripotent stem cell (iPSC) seed stocks using REPROCELL’s StemRNA™ reprogramming platform combined with StemEdit technology.

REPROCELL Co-Authors IBD AI StudySources

REPROCELL Europe scientists co‑authored a Scientific Reports paper showing that biomedical foundation models combined with multi‑omics feature engineering can enhance drug‑response predictions for inflammatory bowel disease patients. The study, which involved partners from IBM Research Europe and the STFC Hartree Centre, highlights the potential of AI‑driven approaches in personalized IBD treatment.

REPROCELL USA Opens GMP Cell FacilitySources

REPROCELL USA Inc. announced the opening of a new GMP‑compliant cell culture facility on April 7, 2026, enhancing its regenerative medicine manufacturing capabilities. The ceremony was attended by President and Global CEO Dr. Yokoyama, CEO Mr. Rama Modali, and Maryland Lieutenant Governor Aruna Miller. The company continues to produce clinical‑grade iPSCs, including its proprietary StemRNA™ Clinical iPSC Seed Clones, in compliance with FDA, EMA, and PMDA standards.

REPROCELL Launches GMP MCB for iPSCsSources

REPROCELL has launched a US FDA‑compliant GMP Master Cell Bank manufacturing service for human induced pluripotent stem cells (iPSCs). The service, based at its Beltsville, Maryland facility, offers an end‑to‑end workflow that includes StemRNA™ clinical seed production, StemEdit gene‑editing, and GMP MCB production.

REPROCELL Adds BioThrust ComfyCell IncuSources

REPROCELL announced the addition of the BioThrust™ ComfyCell Incu bioreactor platform to its product catalogue, enhancing its offerings for advanced human cell culture and stem cell research. The 300 mL single‑use system is designed for intensified and scalable cultivation of sensitive cells. As a licensed worldwide distributor, REPROCELL now provides researchers with access to this innovative technology.

REPROCELL Launches StemEdit Gene EditingSources

REPROCELL announced the commercial launch of StemEdit, its clinical gene editing services and new gene‑edited iPSC product lines that use the AI‑designed OpenCRISPR‑1™ system licensed from Profluent. StemEdit combines REPROCELL’s proprietary clinical gene‑editing technology with StemRNA™ Clinical iPSC Seed Clones, providing GMP‑aligned, traceable, regulatory‑compliant solutions ready for immediate use.

§09

Sources & updates

SOURCES
↑